Matt Fates
Partner - AI VC @ Innospark Ventures
Boston, United States
Matt Fates is a seed investor at Innospark Ventures in Boston focused on Software and Biotechnology. Matt Fates is the Partner - AI VC at Innospark Ventures.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries Matt Fates invests in
Stages Matt Fates invests in
Countries Matt Fates invests in
Investment Focus
Industry
- Software 6 (27%)
- Biotechnology 5 (23%)
- Machine Learning 4 (18%)
- Enterprise Software 4 (18%)
- Artificial Intelligence 4 (18%)
Stage
- Seed 6 (27%)
- Series A 5 (23%)
- Series B 5 (23%)
- Series C 3 (14%)
- Funding Round 1 (5%)
Country
- United States 9 (41%)
- Canada 4 (18%)
- United Kingdom 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Antiverse
|
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $9.3M / Series A / Mar 03, 2026 | |
Phaseshift Technologies
|
PhaseShift Technologies is addressing the critical need for new materials that can overcome limitations in performance, efficiency, cost, availability, and sustainability. Traditional material development relies heavily on trial-and-error, requiring costly and time-consuming physical experiments. This approach can extend projects over 10-20 yearsand cost millions of dollars, with no guarantee of success.PhaseShift's Rapid Alloy Design (RAD)™ technology revolutionizes this process by using AI to create optimized alloys tailored to specific use cases. Paired with Multi-Scale Simulations to accurately predict material performance, RAD™ minimizes the time and effort spent on unsuccessful trials. This leads to faster, more efficient development cycles and a significant reduction in resources required to meet design goals.Through the RAD™ platform, PhaseShift designs a portfolio of innovative alloys, which are commercialized via strategic partnerships with manufacturers. | $3M / Seed / Oct 21, 2024 | |
|
Antiverse
|
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $4.6M / Seed / Oct 15, 2024 | |
BioIntelligence Technologies
|
BioIntelligence Technology develops intelligent monitoring instruments to accelerate bioprocess development for biotechnology industries. They provide solutions for microorganisms or cells to biosynthesize a molecule or a group of molecules. | $3.7M / Seed / Apr 23, 2024 | |
Via Scientific
|
Via Scientific to help scientists and bioinformaticians generate novel science that improves the world. It was founded in 2022. | $5M / Seed / Jan 09, 2024 | |
Persist AI
|
Persist assist pharmaceutical companies in developing long-acting formulations 50% faster. Because the formulation development process is manual and relies on scientific intuition, it takes a pharmaceutical company 5-10 years to develop a long acting formulation for a drug. This effort is divided into five years of pre-clinical development and fiveyears of clinical testing. Their goal is to use machine learning and automation to reduce the time required for pre-clinical formulation development to three months, making the formulation development process 50% faster. | $4M / Seed / Apr 12, 2023 | |
|
Antiverse
|
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $3M / Seed / Mar 01, 2023 | |
Connectbase
|
Connectbase utilizes location-based insights and automation to buy and sell connectivity. Its platform drives growth for the clients by increasing visibility to the market, managing location, and driving engagement as the system of record where connectivity providers connect and pass by in the commercial market. | $21M / Series C / Sep 22, 2022 | |
Dyania Health
|
Dyania Health develops a research platform for pharma companies and hospital systems. Its health platform identifies match patients, then the pharma and CROs send a referral request to the patient’s physician or clinic, and if the patient is the right fit for the clinical trials they can join the trials.The company was founded in 2019 and isbased in Los Angeles, California. | $5.3M / Seed / Sep 08, 2022 | |
ODAIA
|
ODAIA has innovated the first AI-powered Customer Data Platform (CDP) that pioneered the combination of process mining, customer journey mapping and AI to deliver goal-driven commercial insights and process automation as a SaaS for the Life Sciences industry. | $13.8M / Series A / Feb 10, 2022 | |
| See all 22 investments → | |||
Co-Investors
About Innospark Ventures
Innospark Ventures is a new breed of early-stage venture capital firm, investing in the AI-driven economy.
Innospark Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Matt Fates
Partner - AI VC
|
|||
Mark Legare
Venture Investor
|
|||
Venkat Srinivasan
Managing Director
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Matt Fates invest in?
Matt Fates invests primarily in Software, Biotechnology and Machine Learning startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Matt Fates last invest?
The most recent investment recorded for Matt Fates closed in Mar 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
